Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.70 |
| ▸ | RAB9A | P51151 | 12/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.70 |
| ▸ | TP53 | P04637 | 7/20 | 0.70 |
| ▸ | MEN1 | O00255 | 5/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.70 |
| ▸ | RELA | Q04206 | 1/20 | 0.70 |
| ▸ | MAOA | P21397 | 1/20 | 0.68 |
| ▸ | BLVRB | P30043 | 1/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.68 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12171135 | 0.86 | SMN1; SMN2 (0.70) | NPC1RAB9ASMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL8898716 | 0.85 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL7961699 | 0.84 | SMN1; SMN2 (0.81) | NPC1RAB9ASMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL60781 | 0.84 | SMN1; SMN2 (0.69) | NPC1RAB9ASMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL58788 | 0.84 | NR1H4 (0.81) | NPC1RAB9ASMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL60001 | 0.83 | KDM4E (0.70) | NPC1RAB9ASMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL16716023 | 0.82 | SMN1; SMN2 (1.00) | NPC1RAB9ASMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL388703 | 0.82 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL12171886 | 0.81 | PPARD (0.56) | NPC1RAB9ASMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL60427 | 0.81 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9205088-B2 | Compositions of 1,2,4-oxadiazol benzoic acid compounds and methods for their use | PTC THERAPEUTICS, INC. (US) | 2015-12-08 | — | — | US | claimed |
| US-20150148346-A1 | COMPOSITIONS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND METHODS FOR THEIR USE | PTC THERAPEUTICS INC. (US) | 2015-05-28 | — | — | US | claimed |
| US-8975287-B2 | Methods for using 1,2,4-Oxadiazole benzoic acid compounds | PTC THERAPEUTICS, INC. (US) | 2015-03-10 | — | — | US | claimed |
| EP-1618098-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2014-11-19 | — | — | EP | claimed |
| US-20140301978-A1 | METHODS FOR USING 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | PTC THERAPEUTICS INC. (US) | 2014-10-09 | — | — | US | claimed |
| US-8486982-B2 | 1,2,4-oxadiazole benzoic acids | PTC THERAPEUTICS, INC. (US) | 2013-07-16 | — | — | US | claimed |
| US-20120277234-A1 | 1,2,4-OXADIAZOLE BENZOIC ACIDS | PTC THERAPEUTICS, INC. | 2012-11-01 | — | — | US | claimed |
| US-8299105-B2 | 1,2,4-oxadiazole benzoic acid compositions and their use in bioassays | PTC THERAPEUTICS, INC. (US) | 2012-10-30 | — | — | US | claimed |
| US-8227494-B2 | Pharmaceutical compositions of 1,2,4-oxadiazole benzoic acid and their use for the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2012-07-24 | — | — | US | claimed |
| US-20120178080-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOSITIONS AND THEIR USE IN BIOASSAYS | PTC THERAPEUTICS, INC. | 2012-07-12 | — | — | US | claimed |
| US-8163782-B2 | 1,2,4-oxadiazole benzoic acid compositions | PTC THERAPEUTICS, INC. (US) | 2012-04-24 | — | — | US | claimed |
| US-20120087896-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS | PTC THERAPEUTICS, INC. | 2012-04-12 | — | — | US | claimed |
| US-8017636-B2 | 1,2,4-Oxadiazole benzoic acid compositions and their use in bioassays | PTC THERAPEUTICS, INC. (US) | 2011-09-13 | — | — | US | claimed |
| US-20100216851-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOSITIONS AND THEIR USE IN BIOASSAYS | PTC THERAPEUTICS, INC. | 2010-08-26 | — | — | US | claimed |
| US-20100168109-A1 | PHARMACEUTICAL COMPOSITIONS OF 1,2,4-OXADIAZOLE BENZOIC ACID AND THEIR USE FOR THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. | 2010-07-01 | — | — | US | claimed |
| US-7683082-B2 | 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; translation of mRNA is allowed to continue past a nonsense mutation point, resulting in full length protein; genetic disorders; testing whether a compound increases activity of a protein encoded by an mRNA that contains a premature stop codon | PTC THERAPEUTICS, INC. (US) | 2010-03-23 | — | — | US | claimed |
| US-20070161687-A1 | 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; translation of mRNA is allowed to continue past a nonsense mutation point, resulting in full length protein; genetic disorders; testing whether a compound increases activity of a protein encoded by an mRNA that contains a premature stop codon | PTC THERAPEUTICS, INC. | 2007-07-12 | — | — | US | claimed |
| US-7202262-B2 | E.g., 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders | PTC THERAPEUTICS, INC. (US) | 2007-04-10 | — | — | US | claimed |
| US-6992096-B2 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | PTC THERAPEUTICS, INC. (US) | 2006-01-31 | — | — | US | claimed |
| US-20040204461-A1 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | PTC THERAPEUTICS, INC. | 2004-10-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277234-A1 | 1,2,4-OXADIAZOLE BENZOIC ACIDS | UPF1, RIOX2, RPL35A | NPC1 1568/4885RAB9A 3978/4885SMN1; SMN2 22/4885 |
| US-20100168109-A1 | PHARMACEUTICAL COMPOSITIONS OF 1,2,4-OXADIAZOLE BENZOIC ACID AND THEIR USE FOR THE TREATMENT OF DISEASE | UPF1, RIOX2, PABPC1 | NPC1 448/4885RAB9A 3576/4885SMN1; SMN2 5/4885 |
| US-20140301978-A1 | METHODS FOR USING 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | UPF1, RIOX2, RNMT | NPC1 1406/4885RAB9A 4277/4885SMN1; SMN2 63/4885 |
| US-20150148346-A1 | COMPOSITIONS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND METHODS FOR THEIR USE | UPF1, RIOX2, RNMT | NPC1 1473/4885RAB9A 4327/4885SMN1; SMN2 33/4885 |
| US-20120087896-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS | UPF1, RIOX2, RNGTT | NPC1 1977/4885RAB9A 4182/4885SMN1; SMN2 255/4885 |
| US-20100216851-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOSITIONS AND THEIR USE IN BIOASSAYS | UPF1, RIOX2, RNGTT | NPC1 1552/4885RAB9A 4250/4885SMN1; SMN2 44/4885 |
| US-20070161687-A1 | 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; translation of mRNA is allowed to continue past a nonsense mutation point, resulting in full length protein; genetic disorders; testing whether a compound increases activity of a protein encoded by an mRNA that contains a premature stop codon | UPF1, PABPC4, PABPC1 | NPC1 2724/4885RAB9A 3812/4885SMN1; SMN2 135/4885 |
| US-20040204461-A1 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | UPF1, PABPC1, PABPC4 | NPC1 2171/4885RAB9A 3331/4885SMN1; SMN2 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.